Clinical trials have shown that this agent decreases frequency of asthmatic attacks, makes possible reduced concomitant medication, and improves pulmonary function and other parameters of childhood asthma in about four fifths of patients. But it is a prophylactic, not a symptomatic treatment, and does not abolish the need to determine the source of the asthma and provide adequate symptomatic protection against its manifestations.